Safety and Efficacy of Treatment with Sofosbuvir + GS-5816 ± Ribavirin for 8 or 12 Weeks in Treatment-Naïve Patients with Genotype 1-6 HCV Infection...... http://www.natap.org/2014/AASLD/AASLD_12.htm
Safety and Efficacy of Treatment With Interferon-Free, Ribavirin-Free Combination of Sofosbuvir + GS-5816 for 12 Weeks in Treatment-Naïve Patients With Genotypes 1-6 HCV Infection...... http://www.natap.org/2014/EASL/EASL_29.htm
Once-Daily Sofosbuvir With GS-5816 for 8 Weeks With or Without Ribavirin in Patients With HCV Genotype 3 Without Cirrhosis Result in High Rates of SVR12: The ELECTRON-2 Study...... http://www.natap.org/2014/AASLD/AASLD_13.htm
High Efficacy of Treatment With Sofosbuvir + GS-5816 ± Ribavirin for 12 Weeks in Treatment-Experienced Patients With Genotype 1 or 3 HCV Infection....... http://www.natap.org/2014/AASLD/AASLD_32.htm
Evaluation of Transporter and Cytochrome P450-Mediated Drug-Drug Interactions Between Pan-Genotypic HCV NS5A Inhibitor GS-5816 and Phenotypic Probe Drugs..... http://www.natap.org/2014/Pharm/Pharm_36.htm
GS-5816, a Once-Daily NS5A Inhibitor, Demonstrates Potent Antiviral Activity in Patients With Genotype 1-4 HCV Infection in a 3 Day Monotherapy Study...... http://www.natap.org/2013/AASLD/AASLD_13.htm
GS-5816, a Second-Generation HCV NS5A Inhibitor With Potent Antiviral Activity, Broad Genotypic Coverage, and a High Resistance Barrier...... http://www.natap.org/2013/EASL/EASL_34.htm
Gilead Announces Phase 2 Data for Investigational All-Oral Regimen of Sofosbuvir Plus GS-5816 for the Treatment of Chronic Hepatitis C...... http://www.natap.org/2014/AASLD/AASLD_30.htm
